Physician profile
Jay S Fleitman
NPI 1114904497
$34,734.15
in general payments reported to CMS, 2019-2025
44 companies · $1,607 in 2025
The $1,607 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,785 · 2020: $9,242 · 2021: $12K · 2022: $1,229 · 2023: $1,329 · 2024: $4,582 · 2025: $1,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,803 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Education: $91.00 · Travel and Lodging: $24.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,802.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Education | $91.00 |
| Travel and Lodging | $24.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24,450.23 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,944.14 | 2019-2025 | Jardiance, Jascayd, Ofev |
| E.R. Squibb & Sons, L.L.C. | $805.68 | 2021-2025 | Eliquis, Camzyos |
| Harmony Biosciences LLC | $674.40 | 2021-2025 | Wakix |
| Astrazeneca Pharmaceuticals Lp | $569.56 | 2019-2025 | Airsupra, Tezspire, Symbicort |
| Actelion Pharmaceuticals US, INC. | $352.16 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Axsome Therapeutics, INC. | $332.93 | 2023-2025 | Sunosi |
| Amgen INC. | $260.26 | 2021-2025 | Repatha, Tezspire, Repatha |
| Regeneron Healthcare Solutions, INC. | $225.54 | 2022-2025 | Dupixent |
| Genzyme Corporation | $219.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $165.55 | 2019-2023 | Verquvo, Belsomra |
| Jazz Pharmaceuticals INC. | $147.09 | 2019-2022 | |
| Pfizer INC. | $141.44 | 2021-2025 | |
| Grifols USA, LLC | $131.28 | 2019-2023 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $130.14 | 2021-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Fleitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.